Notably, FGFR4 inhibitors also have direct effects on immune cells in the tumor microenvironment, such as myeloid-derived suppressor cells (MDSCs) and M2-type tumor associating macrophages (M2-TAMs). The gene discussed is FGFR4; the disease is neoplasm.